2026
- Preoperative stratification of oncocytic thyroid carcinomas and adenomas using molecular markers pp. 5-16
- Podoplanin as a modern tumor marker: A literature review pp. 5-25
- Soluble forms of the PD-1 receptor and its ligand PD-L1 in the blood serum of breast cancer patients and their relationship with clinical and morphological features of the disease pp. 31-38
2025
2024
- Clinical significance of methylation of lncRNA genes MEG3, SEMA3B-AS1 in tumors of patients with luminal breast cancer pp. 74-83
- Tumor-specific and tumor-associated antigens as targets for immunotherapy pp. 53-66
- Method for detecting perineural and intraneural invasion in breast cancer as a prognostic factor of tumor progression pp. 37-44
- Immune checkpoints and their soluble forms in bone tumors pp. 7-36
2023
- Ovarian cancer and B7-H3 and B7-H4 ligands pp. 36-47
- Serum galectin-3 and -9 and clinical and morphological characteristics of colorectal cancer pp. 17-24
- Endostatin as a biomarker of angiogenesis in patients with bone sarcomas: a systematic review and meta-analysis pp. 6-16
- Galectins: characteristics, role in pathogenesis, clinical course and prognosis of diseases pp. 5-17
- Analysis of methylation levels of miRNA genes in tumors and metastases, taking into account the concentrations of VEGF in the blood plasma of patients with ovarian cancer pp. 5-15
2022
2021
- Key immune checkpoints and their inhibitors in the therapy of bone tumors. Part 2. Additional targets for immunotherapy of bone tumors and markers of its efficiency pp. 18-31
- Key immune checkpoints and their inhibitors in the therapy of bone tumors. Part 1. Signaling system of programmed cell death protein 1 - PD-1/PD-L pp. 5-17
2020
- Genetic predisposition in the formation of the risk of thromboembolism in cancer patients pp. 5-14
- Clinical implication of the programmed cell death-1 protein PD-1 and its ligand PD-L1 in ovarian cancer (review) pp. 5-15
- Genetic predisposition in the formation of the risk of thromboembolism in cancer patients pp. 5-14
2019
2018
2016
2015
- Morphological features of tumors and the matrix metalloproteinases in the blood plasma of patients with gastric cancer pp. 42-48
- MicroRNAS - new promising tumor biological markers and targets for chemotherapy. Part 3. therapeutic use of microRNA. Methods of measuring microRNA concentration pp. 31-39
- MicroRNA - new promising tumor biological markers and targets for chemothe-rapy. Part 2. Clinical studies of microRNA in oncologic diseases pp. 35-50
- Micrornas - new promising tumor biological markers and targets for chemotherapy. Part 1 The history of microRNA discovery, their biogenesis and the use. The role of microRNA as a biomarker pp. 33-43
2014
2013
- Inculin-like growth factors in colorectal cancer patients - serum pp. 69-75
- Evaluation of tumor necrosis factor α and interleukin 6 content in parotid salivary fluid of ductal chronic sialadenitis patients pp. 50-56
- Comparative elisa study of metalloproteinases 2, 7, 9 and their type 2 tissue inhibitor in the tumors and plasma of gastric cancer pp. 48-52
- Clinical prospects of the key NF-B system components study in the tumors of breast cancer patients pp. 66-72
- Genetic studies of bone tumors pp. 5-17
2012
- Molecular biologic markers expression in chondrosarcomas, its association with clinic-morphologic characteristics and prognosis pp. 68-75
- Ewing family tumors (Ewing sarcoma/primitive neuroectodermal tumor ES/PNET). Сlinical and morphologic research pp. 38-42
- Insulin-like growth factors 1 and 2, and insuline-like growth factor binding proteins 1 and 3 in bone tumors pp. 33-37
- Matrix Metalloproteinases and Inflammatory Cytokines Content in oral Fluid of Patients with Different Constructive Materials of Teeth and Denture Restorations pp. 47-51
- Prognostic significance of urokinase and tissue type plasminogen activators and their type 1 inhibitor in the tumors of colorectal cancer oatients: results of 10 years follow-up pp. 42-49
- C-terminale-telopeptide of type I collagen in urine of patients with breast cancer - prognostic factor of bone metastases pp. 3-7
2011
- Clinical Prospects of the Study of NF-κB Signaling Pathway Components Expression and Activity iN tHE Tumors of Breast Cancer Patients pp. 14-23
- Bone Tumors and Levels of Interferon α and γ in Blood Serum pp. 45-50
- The System of Insulin-Like Growth Factors pp. 3-24
- Comparative immunoenzymatic study of nuclear transcription factor NF-κB, its inhibitor IκBα, and upstream effector protein kinase Akt1 expression and activity in the tumors of breast cancer patients pp. 56-61
- Molecular biological markers expression in bone osteosarcomas pp. 55-62